MaxCyte (LON:MXCT) Stock Price Down 0.8% – What’s Next?

MaxCyte, Inc. (LON:MXCT)’s stock price was down 0.8% during mid-day trading on Friday . The company traded as low as GBX 1.26 and last traded at GBX 1.28. Approximately 1,239,267 shares were traded during trading, an increase of 2,846% from the average daily volume of 42,065 shares. The stock had previously closed at GBX 1.29.

MaxCyte Stock Down 0.8%

The firm has a market cap of £1.36 million, a price-to-earnings ratio of -0.03 and a beta of 1.13. The company has a debt-to-equity ratio of 9.70, a current ratio of 12.39 and a quick ratio of 14.38. The stock has a 50-day moving average of GBX 1.11 and a 200-day moving average of GBX 1.03.

MaxCyte Company Profile

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.